Latigo Biotherapeutics, Inc. President and CEO Todd N. Smith filed a Form 4 on November 18, 2026, disclosing the acquisition of employee stock options covering 2,207,516 shares of common stock with a transaction date of November 15, 2026.
Key Highlights
- Reporting person: Todd N. Smith, President and CEO and Director of Latigo Biotherapeutics, Inc. (NASDAQ:LTGO)
- Security acquired: Employee stock option (right to buy) covering 2,207,516 shares of common stock
- Exercise price: $13.11 per share
- Transaction date: November 15, 2026, with an expiration date of November 14, 2036
- Price paid: $0 for the derivative security
- Beneficial ownership following transaction: 2,207,516 derivative securities, held directly
- Vesting schedule: 25% of total shares vest on November 3, 2027, then 1/48th of total shares vest on each monthly anniversary thereafter
Details of the Smith Option Grant at Latigo Biotherapeutics
According to the filing, Todd N. Smith acquired an employee stock option on November 15, 2026, granting him the right to purchase 2,207,516 shares of Latigo Biotherapeutics common stock at an exercise price of $13.11 per share. The option was recorded under Transaction Code "A," indicating an acquisition. The price of the derivative security at the time of the grant was reported as $0. The option is held directly by Smith and expires on November 14, 2036.
The filing discloses the vesting terms as follows: "25% of the total shares subject to this option shall vest on November 3, 2027, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof." No shares are reported as exercisable before the initial cliff date. Following the reported transaction, Smith's total beneficial ownership of this derivative security stands at 2,207,516 shares, with no non-derivative securities reported in Table I of this filing.
The Form 4 was signed by Sabrina Nieder as attorney-in-fact on November 18, 2026, and filed on that same date. No amendment date was indicated, and the filing was made by one reporting person. The issuer is identified as Latigo Biotherapeutics, Inc., trading on NASDAQ under the symbol LTGO, with its address listed as 1300 Rancho Conejo Blvd., Suite 305, Thousand Oaks, California 91320.
What Was Disclosed
This Form 4 discloses the grant of a stock option to Latigo Biotherapeutics President and CEO Todd N. Smith, covering 2,207,516 shares of common stock at a $13.11 exercise price, with a ten-year term and a four-year vesting schedule beginning November 3, 2027.





Please wait processing your request...